• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

NIHR Oxford Health Biomedical Research Centre

MENUMENU
  • About
    • About
    • Management and core team
    • Our partners
    • Timeline of our key achievements
    • Core facilities
    • Work with us
    • Contact
  • Departments
    • NIHR Oxford Cognitive Health Clinical Research Facility
    • Brain Health Centre
    • Oxford Precision Psychiatry Lab (OxPPL)
    • Oxford Dementia and Ageing Research (OxDARE)
    • Treatment Resistant Depression Clinic
    • Experimental Medicine and Industry Partnership (EMIP)
  • Research Themes
    • Better Sleep
    • Brain Technologies
    • Data Science
    • Dementia
    • Depression Therapeutics
    • Flourishing & Wellbeing
    • Mental Health in Development
    • Molecular Targets
    • Pain
    • Preventing Multiple Morbidities
    • Psychological Treatments
  • COVID-19 Research
    • Overview
    • News
    • COVID-19 & clinical management of mental health issues
  • News & Events
    • News
    • Training and Events
    • Psychiatry Department Seminars
  • Patients & Public
    • About Patient and Public Involvement
    • Shape our research
    • Take part in our research
    • Resources for researchers
    • Resources for the public
    • Patient and Public Involvement Strategy
    • Young people’s involvement
  • Training Hub
You are here: Home / Departments / NIHR Oxford Health Experimental Medicine and Industry Partnership (EMIP)

NIHR Oxford Health Experimental Medicine and Industry Partnership (EMIP)

The Experimental Medicine and Industry Partnership (EMIP) has been established at the Oxford Health BRC to support commercial organisations who are looking to implement experimental medicine approaches in their psychiatric treatment development programmes.

The BRC partners – Oxford University and Oxford Health NHS Foundation Trust – are home to some of the world’s leading basic, clinical and translational neuroscience researchers, with expertise and experience that are critical for the effective application of experimental medicine approaches to psychiatric drug development programmes.  They have an established track record of successful collaboration with industry and facilitating the successful translation of evidence from preclinical models to early clinical trials. 

Human neurocognitive mechanistic markers of psychiatric drug action developed in Oxford have been implemented across the world in early phase clinical trials in order to:

  • Screen and predict the effects of novel candidate treatments prior to large scale efficacy testing
  • De-risk compound development
  • Facilitate decision making and improve subsequent trial design
  • Predict treatment response

What does EMIP do?

The EMIP provides tailored peer review of experimental medicine clinical development strategies and advice on how to optimise the application of human models and biomarkers to psychiatric drug development, drawing on Oxford’s expertise in cognitive neuroscience, pharmacology, neurostimulation, neuroimaging, sleep, digital wearables, drug repurposing, psychological treatment, lifestyle interventions, gut health and precision psychiatry.

Outcomes from our consultation process can include:

  • Assisting with the application of validated experimental medicine approaches in treatment development for psychiatry
  • Support with project/programme development and delivery locally or through national or international networks
  • Sign-posting to commercial or academic partners who would be best placed to deliver the proposed suggestions
  • Assisting with the development of funding proposals for submission to grant/governmental funding bodies or investors

For more information about EMIP, or to make an initial enquiry please contact Dr Susannah Murphy


AIMday in Experimental Medicine in Psychiatry

The EMIP was launched with an AIMday in Experimental Medicine in Psychiatry industry event.  The AIMday format allows industry to propose challenges for one-hour roundtable discussions with groups of relevant academics and clinicians from Oxford. You can read a selection of blogs from the AIMday sessions in the collection below.

Experimental Medicine AIMday July 2021

Participating companies include:

Primary Sidebar

News Categories

  • News
    • Clinical Research Facility
    • COVID-19 research
      • Children, young people and family mental health
      • COVID-19 and psychiatric diagnosis
      • Online therapies and resources for clinicians
      • Patient and Public Involvement in the pandemic
      • PHOSP COVID
      • Vaccination and vaccine hesitancy
    • Research Themes
      • Better Sleep
      • Brain Technologies
      • Data Science
      • Dementia
      • Depression Therapeutics
      • Flourishing & Wellbeing
      • Mental Health in Development
      • Molecular Targets
      • Pain
      • Preventing Multiple Morbidities
      • Psychological Treatments
    • Training and Development
Tweets by OxHealthBRC
Follow @OxHealthBRC

Footer

Follow us

  • LinkedIn
  • Twitter
  • YouTube

Improving brain health: the future in mind

The National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) is a partnership between Oxford Health NHS Foundation Trust and the University of Oxford.  We are part of the Oxford Academic Health Partners.
Oxford Academic Health Partners
  • Sitemap
  • Accessibility
  • Disclaimer
  • Cookies
  • Contact

© 2023 NIHR Oxford Health Biomedical Research Centre · Log in

Cookies

This site uses cookies: See our privacy policy